Printer Friendly

UNIMED, LECTEC TO PURSUE TRANSDERMAL DEVELOPMENT OF MARINOL

    UNIMED, LECTEC TO PURSUE TRANSDERMAL DEVELOPMENT OF MARINOL
    SOMERVILLE, N.J., Jan. 24 /PRNewswire/ -- UNIMED, Inc. (NASDAQ: UMED) and LecTec Corporation (NASDAQ: LECT) today announced the signing of an agreement to develop UNIMED's Marinol(R) (dronabinol) in a novel transdermal drug delivery system.
    Under the terms of the agreement, LecTec will develop and refine a suitable transdermal system with Marinol supplied by UNIMED.
    Marinol, currently marketed as an antinausea pharmaceutical for the treatment of cancer chemotherapy patients, is undergoing Phase III multicenter studies for appetite stimulation and prevention of weight loss in AIDS patients.  Marinol has been granted Orphan Drug status for this use.  Enrollment targets for Phase III studies have been achieved and filing of a Supplemental New Drug Application for this new indication is scheduled for July 1992.
    UNIMED, Inc. specializes in the development and marketing of pharmaceuticals, with emphasis on therapy and supportive care of cancer patients and AIDS patients.  The company has brought two pharmaceuticals to market and has a portfolio of drugs in development.
    LecTec Corporation is a medical products development and manufacturing company headquartered in Minnetonka, Minn.  The company manufactures transdermal drug delivery systems, cardiac electrodes, medical tapes and conductive-adhesive membranes for various electromedical devices.
    -0-        1/24/92
    /CONTACT:  Charles P. Harrison, president of UNIMED, 908-526-6894, or George Ingebrand, president and CEO of LecTec, 612-933-2291/
    (UMED) (LECT) CO:  UNIMED, Inc.; LecTec Corporation ST:  New Jersey, Minnesota IN:  MTC SU:  PDT PS -- NY003 -- 3151 01/24/92 09:20 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 24, 1992
Words:246
Previous Article:KIMBALL COMPLETES PURCHASE OF HARPERS
Next Article:IBERIA AIRLINES MOVES U.S. CORPORATE HEADQUARTERS TO MIAMI
Topics:


Related Articles
LECTEC BOARD APPROVES ADDED EMPHASIS ON TRANSDERMAL BUSINESS DEVELOPMENT; CITES SIGNIFICANT OPPORTUNITIES
UNIMED HITS ENROLLMENT TARGET FOR MARINOL PHASE III STUDIES IN AIDS PATIENTS
LECTEC BOARD INTENSIFIES FUNDING FOR TRANSDERMAL PATCH DEVELOPMENT; TO TREAT SMOKERS, CANCER PATIENTS, OTHERS
LECTEC TO LAUNCH NEW PRODUCT FOR TREATMENT OF BED SORES AND OTHER CHRONIC WOUNDS
MARINOL RECEIVES APPROVAL AS THE FIRST MEDICATION FOR ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS
UNIMED PHARMACEUTICALS STARTS CRYPTOSPORIDIUM CLINICAL TRIAL
UNIMED PHARMACEUTICALS BEGINS GERIATRIC HYPOGONADISM (ANDROPAUSE) CLINICAL TRIAL
UNIMED PHARMACEUTICALS BEGINS HYPOGONADISM CLINICAL TRIAL; TRIGGERS SECOND BIOCHEM MILESTONE PAYMENT
Marinol Found Promising in Treatment of Geriatric Patients with Alzheimer's
Alzheimer's Disease Experts Join Unimed Advisory Board

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters